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Los Angeles, California; and Baltimore, Maryland
Objectives The aim of this study was to quantify acute myocardial retention of cardiac-derived stem cells (CDCs) and evalu-
ate different delivery methods with positron emission tomography (PET).
Background Success of stem cell transplantation for cardiac regeneration is partially limited by low retention/engraftment of
the delivered cells. A clinically applicable method for accurate quantification of cell retention would enable opti-
mization of cell delivery.
Methods The CDCs were derived from syngeneic, male Wistar Kyoto (WK) rats labeled with [18F]-fluoro-deoxy-glucose
(18FDG) and injected intramyocardially into the ischemic region of female WK rats after permanent left coronary
artery ligation. The effects of fibrin glue (FG), bradycardia (adenosine), and cardiac arrest were examined. Imag-
ing with 18FDG PET was performed for quantification of cell retention. Quantitative polymerase chain reaction
(PCR) for the male-specific SRY gene was performed to validate the PET results.
Results Myocardial retention of cells suspended in phosphate-buffered saline 1 h after delivery was 17.6  11.5% by
PCR and 17.8  7.3% by PET. When CDCs were injected immediately after induction of cardiac arrest, retention
was increased to 75.6  18.6%. Adenosine slowed the ventricular rate and doubled CDC retention (35.4 
5.3%). A similar increase in CDC retention was observed after epicardial application of FG at the injection site
(37.5  8.2%). The PCR revealed a significant increase in 3-week cell engraftment in the FG animals (22.1 
18.6% and 5.3  3.1%, for FG and phosphate-buffered saline, respectively).
Conclusions In vivo PET permits accurate measurement of CDC retention early after intramyocardial delivery. Sealing injec-
tion sites with FG or lowering ventricular rate by adenosine might be clinically translatable methods for improv-
ing stem cell engraftment in a beating heart. (J Am Coll Cardiol 2009;54:1619–26) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.097m
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rtem cell transplantation is a promising new treatment
odality for chronic ischemic cardiomyopathy (1). Several
ifferent types of stem and progenitor cells have been used
or this purpose (2,3). Experimental and small-scale clinical
tudies have provided encouraging albeit inconsistent and
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ccepted April 13, 2009.odest functional improvement. There are still many issues
o be resolved, related to the optimal cell type, mechanism
f efficacy, timing, and route of cell delivery. Low cell
etention and engraftment are major obstacles to achieving
significant functional benefit irrespective of the cell type or
odel used (4,5).
See page 1627
To address this problem, several methods for quantifica-
ion of stem cell engraftment have been used (namely direct
ell radiolabeling, genetic labeling with reporter genes, and
eal-time quantitative polymerase chain reaction [qPCR])
4–14). All these techniques have revealed that acute cell
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PET for Cardiac Stem Cell Delivery Assessment October 20, 2009:1619–26retention is 10%, after in-
tramyocardial, intracoronary, or
retrograde transvenous cell deliv-
ery, emphasizing the inefficiency
of the currently used methods for
intracardiac stem cell transplan-
tation (5). There is a clear need
for a noninvasive, accurate, and
readily translatable technique for
quantification of cell engraftment
that would allow rapid assess-
ment of the efficacy of any cell
delivery strategy. Within this
context, in vivo imaging can play
a major role (15,16).
Here we used positron emis-
sion tomography (PET) for in
vivo quantification of retention
of [18F]-fluoro-deoxy-glucose
(18FDG) labeled cells after di-
rect intramyocardial delivery, in
a rat myocardial infarction (MI)
model. We validated the quanti-
tative data derived noninvasively
by PET with one of the most
ensitive laboratory techniques (qPCR). With PET as a
ool, we investigated the role of cardiac contraction and
erfusion on cell retention, and we tested various interven-
ions to optimize cell delivery, namely a mechanical plug at
he site of injection, and drugs to lower heart rate or to
uppress contractility. Sealing the injection site with fibrin
lue (FG) and lowering heart rate by adenosine significantly
mproved cell retention. Importantly, the former interven-
ion translated into a longer-term boost of engraftment and
unctional improvement in the same model.
ethods
ells. Cardiac-derived stem cells (CDCs) were cultured
rom tissue samples derived from explanted hearts from
ale 3-month-old Wistar Kyoto (WKY) rats (Harlan,
ndianapolis, Indiana), as previously described (17,18). The
KY are inbred syngeneic rats and therefore appropriate
or use in cell transplantation studies, without the need for
mmunosuppression (19,20).
n vitro 3H-FDG labeling. The 105 cells were incubated
n glucose-free medium for 1 h and exposed to 2 Ci/ml of
H-FDG with or without insulin (0.1 U/ml) for 30 or 60
in. Tracer uptake was measured by beta-counting.
adiotoxicity of 18FDG. To assess toxicity of 18FDG,
,000 cells were incubated with 2 Ci /ml of media 18FDG.
imilar number of cells in regular media served as controls.
ell viability and proliferation were examined by a WST-8
olorimetric assay (Cell Counting Kit-8, Dojindo Molecular
echnologies, Rockville, Maryland), as per the manufac-
Abbreviations
and Acronyms
18FDG  [18F]-fluoro-
deoxy-glucose
BDM  2,3-butanedione-
2-monoxime
CDC  cardiac-derived
stem cells
CT  computed
tomography
FAC  fractional area
change
FG  fibrin glue
MI  myocardial infarction
PBS  phosphate-buffered
saline
PCR  polymerase chain
reaction
PET  positron emission
tomography
qPCR  quantitative
polymerase chain reaction
WKY  Wistar Kyotourer’s protocol.
B
pnimal model. Female WKY rats (n  85 total) under-
ent left thoracotomy under general anesthesia, and MI was
roduced by permanent ligation of the left anterior descend-
ng coronary artery. The CDCs (2 million, suspended in
50 l of phosphate-buffered saline [PBS]) were injected
irectly into the myocardium, at 2 sites into the infarct.
ubsequently, the chest was closed, and the animals were
ransported to the PET scanner. Animal care was in accor-
ance to Johns Hopkins University guidelines (details are
rovided in the Online Appendix).
ell injections. Two million CDCs were labeled with
8FDG immediately before injection (Table 1). Subse-
uently, cells were pelleted by centrifugation for removal of
abeling media and washed twice in PBS.
To explore the role of cardiac contraction and coronary
lood flow on CDC retention, cardiac arrest was induced in
animals by IV thiopental injection through the tail vein.
fter cardiac arrest was confirmed by visual inspection, cells
ere injected at 2 sites of the left ventricle. Subsequently,
he chest was closed, and the animals underwent PET
maging 1 h after the injection.
In 8 animals, (FG group) cells were injected intramyo-
ardially, in 2 sites, within the infarct border zone. While
he needle tip was still in situ, 1 or 2 drops of FG (Tisseel
H-Baxter Healthcare Corp., Glendale, California) were
pplied directly over each injection site, to provide a seal and
revent backwash of the cells. In 8 animals (cells in PBS
roup), similarly labeled cells were injected without appli-
ation of FG.
To determine whether transient suppression of myocar-
ial contraction locally at the site of cell injection could
mprove retention, cells were resuspended in 150 l of PBS
ontaining 100 mol/l 2,3-butanedione-2-monoxime
BDM) (Sigma-Aldrich, St. Louis, Missouri), an
xcitation-contraction uncoupler (21), and then injected in
he myocardium of infarcted rats (n  6).
escription of the Study GroupsTable 1 Description of the Study Groups
Experimental Group n Protocol of Cell Injection
Cardiac arrest 4 Cells were injected intramyocardially after the
induction of cardiac arrest
Lysed cells 2 Cells were lysed with sonication after labeling
and before injection
Cells in PBS 8 Cells were suspended in PBS and injected
intramyocardially
BDM 6 Cells were suspended in PBS containing
100 mol/l of BDM to locally suppress
contractility at the injection site
FG 8 After intramyocardial cell injection, the epicardial
side of the injection site was sealed by FG
Adenosine 4 Intramyocardial delivery of cells was performed
during slowing of ventricular rate by
IV injection of adenosine (1 mg)
FG  adenosine 8 Cell delivery was performed during IV adenosine
injection and subsequently the injection site
was sealed epicardially by FGDM  2,3-butanedione-2-monoxime; FG  fibrin glue; FAC  fractional area change; PBS 
hosphate-buffered saline.
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October 20, 2009:1619–26 PET for Cardiac Stem Cell Delivery AssessmentBecause rats have a heart rate of 300 to 400 beats/min
22), we sought to determine whether the slowing of
entricular rate by the IV injection of adenosine (1 mg)
mmediately before cell delivery would lead to an increase of
cute cell retention, by improving the accuracy of the cell
njection (n  4).
Additionally, in 8 animals, IV adenosine was combined
ith epicardial FG, to investigate any potential synergistic
ffect of these 2 interventions.
Finally, to investigate whether radioactivity derived
rom dead cells could confound quantification, 2 million
DCs were radiolabeled and subsequently lysed by son-
cation. The lysate was then injected intramyocardially at
sites of the infarct border zone, in similarly infarcted
istar Kyoto rats (n  2).
n vivo imaging. The PET images were acquired on a GE
ISTA (GE Healthcare, Piscataway, New Jersey) small
nimal PET system. Features of this system have been
ublished before (23). Details about the imaging protocol
an be found in the Online Appendix.
A static PET acquisition of the syringe containing the
abeled cells (5 min) was obtained immediately before cell
njection. After cell injection, the same syringe was imaged
gain (same imaging parameters), to calculate the net
njected radioactivity (that corresponds to the exact cell
umber delivered in every animal).
After the completion of the 18FDG acquisition, a perfu-
ion PET study with 13NH3 (ammonia) was performed for
yocardial delineation (Online Appendix).
After the perfusion scan, [18F]-fluoride was injected to
acilitate the co-registration of PET and computed tomog-
aphy (CT) images obtained with the different scanners as
reviously described (Online Appendix) (13). The use of
icro CT for attenuation correction of micro PET images
as recently been shown to be the most accurate technique
or this purpose and has been applied in integrated
ET/CT scanners (24).
mage analysis. All images were analyzed with AMIDE
oftware (Online Appendix) (25).
uantification of engraftment by real time PCR. Quan-
itative PCR was performed 1 h after cell injection in 6
nimals (cells in PBS group) and in 16 at 21 days after cell
njection (8 of the FG and 8 of the cells in PBS group) to
alidate the results obtained by PET but also to compare
edium term engraftment in these groups. We injected
ells isolated from male donor WK rats into the myocar-
ium of female recipients and quantified engrafted donor
ell numbers, as a function of time, by real-time PCR, with
he SRY gene located on the Y chromosome as target
Online Appendix) (4).
chocardiography. To assess global cardiac function in 39
ats (cells in PBS [n  11], FG [n  11], control group
here PBS only was injected [n  9], and control group
here FG was applied epicardially after PBS injection (n 
]), echocardiography was performed with the Vevo 770
ystem (Visualsonics, Toronto, Canada) on days 2 and 21 tfter the induction of MI. The fractional area change
%FAC) was measured on the parasternal long-axis view,
nd changes from baseline (day 2 after MI) are reported.
istology. In 6 animals (3 of the cells in PBS group and 3
f the FG group) enhanced green fluorescent protein
abeled cells were injected to allow detection by immuno-
ytochemistry (Online Appendix).
tatistical analysis. Values are reported as mean  SD.
he Student t test was used to compare cell retention rates,
ngraftment, and ejection fractions, when comparisons were
erformed between 2 independent groups. The t test with
he Welch’s correction was used when the assumption of
qual variances was not satisfied. One-way analysis of
ariance was used when the groups were 3 or more, and the
unnett’s test was applied for post-hoc comparisons be-
ween the baseline group and the intervention groups. A
value 0.05 was chosen for statistical significance.
esults
adiolabeling of CDCs with 18FDG. Accumulation of
FDG in CDCs was 2.2  1.3% of the administered dose
fter 30 min of exposure and did not show any significant
hange after 60 min or after addition of insulin in the
abeling medium (data not shown). With 18FDG for label-
ng, 2 Ci/ml had no affect on cell viability and proliferation
or up to 7 days after labeling (data not shown). On the basis
f these findings, radiolabeling CDCs with a dose of 2
Ci/ml of media for 30 min was selected for in vivo
xperiments.
n vivo PET imaging. Normally perfused myocardium
as delineated by 13NH3 perfusion imaging. The infarct
egion appeared as a large anterolateral perfusion deficit.
njected cells were easily identified as intramyocardial bright
pots by PET, localized within the infarct area and infarct
order zone (Figs. 1A to 1C). Coregistration with CT was
uccessful in all animals (Figs. 1D to 1F), allowing accurate
n vivo quantification of cell retention.
etention of intramyocardially injected cells. When
onviable (lysed) cells were injected, %ID was 6.4  4.3%,
ndicating low reuptake of the released radiolabel by the
yocardium.
In the animals that received cells resuspended in plain
BS, retention 1 h after injection was 17.8  7.3%, a low
etention rate that is in accordance with previous studies
hat quantified efficiency of cell delivery by ex vivo
ethods (4,5).
When cells were injected in the arrested heart, retention
ncreased to 75.8  18.3% (p  0.01 vs. cells in PBS). The
rrested heart does not contract or sustain perfusion. Thus,
ardiac contraction and/or coronary perfusion are major
otential culprits in the early washout of cells from the
njection site.
One way that contraction might affect cell retention is by
ctive extrusion of the injectate during each heartbeat. We
ested this notion by creating a mechanical plug with FG at
t
g
(
s
c
l
e
p
c
0
o
a
a
d
t
d
p
e
w
r
t
fi
i
t
s
t
e
a
V
a
i
1
P
i
L
c
e
e
q
e
5
i
i
t
1622 Terrovitis et al. JACC Vol. 54, No. 17, 2009
PET for Cardiac Stem Cell Delivery Assessment October 20, 2009:1619–26he site of injection, so as to minimize backwash. In the FG
roup, retention was significantly increased to 37.5  8.2%
p  0.01 vs. cells in PBS), revealing a dramatic effect of
ealing the injection site on cell retention.
Another approach to minimize the effects of cardiac
ontraction is to slow the heart rate. Adenosine injection
owered the heart rate in all animals of the group and
xerted a favorable effect on cell retention (35.4  5.3%,
 0.05 vs. cells in PBS). When IV adenosine was
ombined with FG use, retention was 39.3  11.6% (p 
.01 vs. cells in PBS). The fact that no significant increase
f cell retention over the levels achieved by either technique
lone was observed indicates that mean retention rates of
pproximately 40% are probably the limit in our model. The
ifference between 40% and the approximately 75% seen in
he arrested heart likely reflects the contribution of myocar-
ial perfusion on cell washout from the injection site.
Yet another approach to decrease cardiac contraction is to
aralyze the heart locally with a drug that uncouples
xcitation from contraction. Local injection of BDM along
ith the CDCs did not result in any improvement of cell
etention (14.9  6.9%, p  NS vs. cells in PBS), despite
he fact that contractility was transiently suppressed, con-
Figure 1 Detection of 18FDG Labeled Cells Injected in the Myo
(A) Transverse, (B) coronal, (C) sagittal image orientation. In a different experime
(PET) images provides more detailed anatomical information. (D) Transverse, (E)
deoxy-glucose.rmed by visual inspection at the injection site. The anadequacy of this intervention was probably due to its very
ransient nature: normal contraction resumed visually a few
econds after BDM injection, reflective of quick washout of
he drug from the injection site.
Comparisons of acute cell retention between the different
xperimental groups are summarized in Figure 2 (1-way
nalysis of variance, p  0.0001).
alidation of PET quantitative results by qPCR. In 6
nimals of the PBS group, retention at 1 h after cell
njection, measured by quantitative real-time PCR, was 17.6
1.5%, almost identical to the values obtained by in vivo
ET, underscoring the accuracy of quantification with this
maging modality (Fig. 3).
onger-term engraftment. To determine whether the in-
rease of acute cell retention would have an impact on cell
ngraftment 3 weeks after cell transplantation, we compared
ngraftment between the cells in PBS and FG groups, with
uantitative real-time PCR. Indeed, in the FG group, cell
ngraftment was significantly augmented (22.1  18.6% vs.
.3  3.1%, p  0.039), indicating that an effective early
ntervention aimed at improving retention of cells in the
nfarcted myocardium could have important implications for
he sustained presence of these cells in the heart (Fig. 4). In
um by Micro-PET
ion of computed tomography (CT) and micro-positron computed tomography
al, (F) sagittal image orientation. 13NH3  13N-ammonia; 18FDG  [18F]-fluoro-cardi
nt, fus
coronddition, at 3 weeks, green fluorescent protein positive cells
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October 20, 2009:1619–26 PET for Cardiac Stem Cell Delivery Assessmentere identified by immunocytochemistry in the infarct
order zone of 2 of 3 animals of the FG group only,
onfirming their stable engraftment (Fig. 5).
unctional effect of CDC transplantation. Baseline FAC
as 62  10% in the experimental animals. On day 2 after
nduction of MI, FAC was 39.3  7.1%, 39.1  9.9%,
2.5  9.7%, and 41.6  11% in the PBS only, FG only,
ells in PBS, and cells with FG groups, respectively,
ndicating that infarct sizes were comparable in all groups.
n animals that received injection with vehicle only (PBS
ithout or with FG), FAC decreased from day 2 to day 21
fter MI (25.9 23.5% and7.6 37.2%, respectively).
n contrast, in both cells in PBS and FG groups, FAC was
ignificantly improved from day 2 to day 21, when com-
ared with the placebo group of PBS injection only (7.9
5.6% and 24.3  31%, p  0.05 and p  0.01 vs. PBS
Figure 2
Retention of Intramyocardially
Injected Cells at 60 min After Cell
Injection, in the Different Experimental Groups
The p values correspond to comparisons between the cells in phosphate buff-
ered saline (PBS) and the intervention groups. Values are reported as mean 
SD. Aden  adenosine; BDM  2,3-butanedione-2-monoxime; FG  fibrin glue.
Figure 3
Retention of Intramyocardially Injected
Cells 60 min After Cell Injection Measured
by In Vivo PET and Real-Time Quantitative PCR
Cells in phosphate buffered saline group-values are reported as mean  SD.
PCR  polymerase chain reaction; PET  positron computed tomography.nly, respectively). Although there was a trend for greater
ncrease in the FG group, in comparison with cells in PBS
indicating that optimizing acute cell retention and engraft-
ent translates to a superior functional benefit, in this
odel), this did not reach statistical significance, probably
ecause of the large variability (Fig. 6).
iscussion
cute retention of cells delivered directly into the myocar-
ium is low, compromising the potential of stem cell
herapy for myocardial regeneration. In the present study,
e applied a safe, nontoxic method for cardiac stem cell
Figure 4 Comparison of Engraftment at 3 Weeks
Between the Cells in PBS and FG Groups
Assessment by real-time quantitative polymerase chain reaction, values are
reported as mean  SD. FG  fibrin glue; PBS  phosphate-buffered saline.
Figure 5 Immunocytochemistry of Frozen Cardiac
Sections at 3 Weeks After Cell Injection
The presence of enhanced green fluorescent protein positive cells (green) at
the infarct border zone (red: troponin I), in an animal of the fibrin glue group,
was revealed.
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PET for Cardiac Stem Cell Delivery Assessment October 20, 2009:1619–26adiolabeling; we quantified cell retention by in vivo PET
maging and developed methods for significantly improving
he efficiency of intramyocardial injections, with clinically
pproved compounds.
Many studies in the past acknowledged the problem of
ow engraftment as one of the main hurdles to a significant
unctional improvement after stem cell transplantation
4,5,11,26). To address this issue, an easily applicable and
otentially translatable method is required for quantitative
ssessment of cell delivery. Positron emission tomography
maging is particularly attractive for this purpose, because it
s noninvasive, sensitive, readily quantifiable, and widely
sed in clinical practice.
In vivo PET imaging presents a significant advantage
ver the other available techniques for assessing engraft-
ent, because it allows relative quantification of acute cell
etention as a percentage of the net injected activity, thus
liminating errors resulting from cell counting or from
esidual cells in the dead space of the syringe. In addition,
irect radiolabeling presents significant advantages over a
eporter gene technique for quantification purposes, because
o systemic tracer injections are needed. Thus, the back-
round is minimal, very small numbers of cells can be
etected, and the dose of the radiolabel can be kept to very
ow levels, without sacrificing sensitivity.
Single-photon emission tomography has also been used
or short-term tracking of injected cells (7,9,10,12). The
nherent lower sensitivity of this modality necessitates the
se of relatively large doses of radioactivity to label the cells
nd obtain adequate images within reasonable time, raising
he risks of radiotoxicity (reduced viability or proliferation
ates), particularly in sensitive cell types. Several studies have
eported substantial toxicity from 111-indium on labeled
tem cells (7,12,27). In addition, quantification of single-
Figure 6
Percent Change in FAC Between Days 2 and
21 After Myocardial Infarction, in Animals Treated
With Cells in PBS, Cells and FG, PBS Only, and FG Only
One-way analysis of variance, p  0.002. The p values on the figure corre-
spond to post hoc comparisons between the PBS only and the intervention
groups. Values are reported as mean  SEM. FAC  fractional area change;
other abbreviations as in Figures 2 and 3.hoton emission tomography images remains challenging, Aainly due to the significant confounding effect of scatter-
ng (28).
Several groups in the past have used 3-dimensional
njectable scaffolds as vehicle for cell implantation and have
eported improved results (29). Within this context, fibrin
glue’ seems a particularly attractive option, because it has
lready been approved for clinical use (30–34). It consists of
components, a thrombin/calcium chloride and a fibrino-
en/aprotinin solution that are mixed immediately before
pplication. In previous reports, FG was used to facilitate
elivery of endothelial cells, skeletal myoblasts, or bone
arrow mononuclear cells in the infarcted myocardium
31,32,34). This approach led to an improved functional
utcome that was attributed to a higher engraftment rate,
lthough the latter was not documented directly by any
uantitative technique. In addition, in all these studies, cells
nd the 2 components of the glue were mixed, creating an
nvironment that might promote cell clumping or intravas-
ular thrombus formation. In all intramyocardial injections,
fraction of the cells will be either inadvertently injected in
he left ventricular cavity and end up in the microcirculation
f peripheral organs or will migrate through the cardiac
enous system to the right heart and eventually reach the
ungs. Fibrin glue solidifies fast after application, enabling
he encapsulated cells to create large aggregates within the
-dimensional scaffold. These aggregates have the potential
o embolize, a risk that could preclude clinical application of
his material for cell delivery. In addition, the risk of
nducing intravascular thrombosis when the thrombin com-
onent is injected intravascularly has been recognized in
linical applications, further raising concerns about the
afety of the practice of mixing the cells with the compound
nd injecting it in the myocardium (35,36).
In the present study, we applied the FG exclusively on the
picardium, to either prevent back leak of injected cells due
o myocardial contraction or washout by bleeding caused by
he injection trauma. We were able to confirm a significant
ncrease in cell retention by PET, and importantly, we
howed a benefit in cell engraftment at 3 weeks and a trend
oward larger functional benefit. Our modified protocol
aintained efficacy while minimizing potential risks, sug-
esting potential for future clinical applications.
Optimization of cell retention by FG should be con-
rmed, however, in more clinically relevant models before
se in clinical trials of stem cell therapy is attempted. In
arger models, the relative volume of the injectate in relation
o the myocardial mass is smaller; therefore back leak of cells
fter intramyocardial injection might be less pronounced,
nd the need for sealing the injection site might be smaller.
Adenosine was also proven effective in increasing acute
DC retention in the rat model. Although cell injection
uring adenosine infusion could be easily attempted in the
linical setting, it is difficult to predict the impact of this
pproach, because heart rates are significantly lower in
umans, and injections are less demanding technically.
denosine, in the doses that can be used safely in clinical
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October 20, 2009:1619–26 PET for Cardiac Stem Cell Delivery Assessmentpplications, might lead to a significant increase in coronary
lood flow, exaggerating the washout of cells from the
yocardium. Adenosine has been recently reported to
ncrease the adhesion of endothelial progenitor cells in the
oronary microcirculation and increase their cardiac reten-
ion, through up-regulation of P-Selectin on endothelial
ells (37). This effect is rapid and thus might have played a
ole in the improved CDC retention we observed with
denosine, although our initial rationale was purely to effect
egative chronotropy.
Nevertheless, both FG and adenosine should be tested in
arge animal models that are more clinically relevant, to
etermine their true potential. Positron emission tomogra-
hy seems to be the method of choice to reliably quantify
ell retention and to evaluate these and any other cell
elivery techniques.
tudy limitations. Despite the numerous advantages of
ET, the short half-life of most of the available tracers
ignificantly diminishes the potential applications. [18F]-
uoro-deoxy-glucose PET can only be used for tracking the
ells within the first few hours after delivery, because this
racer has a half-life of 110 min. However, successful
abeling of cells with the PET tracer 64Cu-PTSM has been
eported (half-life of 12.7 h), allowing longer-term cell
etection (38). In addition, PET availability remains limited
o larger centers, although this situation is rapidly changing.
espite these facts, the quality and reproducibility of the
esults are favorable aspects of this technology for accurate
uantification of acute cell retention. Finally, the impact of
ncreased acute retention on long-term engraftment and
ardiac function in the adenosine group was not assessed in
he present study and should be demonstrated in future
xperiments.
onclusions
n vivo PET imaging is an effective, accurate, clinically
ranslatable approach for measurement of acute cell reten-
ion after intramyocardial cell injection. It permits assess-
ent of different delivery methods and can contribute to
ptimization of cellular therapies and functional benefits of
ransplantation. With PET, we have compared several
ethods for improving intramyocardial cell delivery and
hown that sealing of the epicardial injection site with FG
nd reduction of ventricular rate by IV adenosine can
ignificantly improve cell retention.
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